Patents Issued in March 5, 2020
  • Publication number: 20200069622
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Publication number: 20200069623
    Abstract: The present invention relates to the treatment of sepsis and sepsis-associated acute kidney injury (SA-AKI). More specifically, it relates to cilastatin for use in a method of treating sepsis and/or SA-AKI and reducing its associated mortality, in a mammalian subject. It is further directed to methods for treating sepsis and/or SA-AKI; and to pharmaceutical compositions for use in the methods of the invention.
    Type: Application
    Filed: June 23, 2017
    Publication date: March 5, 2020
    Inventors: Alberto TEJEDOR JORGE, Alberto LAZARO FERNANDEZ, Blanca HUMANES SANCHEZ, Maria Angeles GQNZALEZ-NICOLAS GONZALEZ
  • Publication number: 20200069624
    Abstract: Methods of normalizing amino acid metabolism in subjects on restricted protein diets and supplemental amino acids, using specially formulated amino acids that mimic the absorption and metabolism of naturally occurring proteins, are described.
    Type: Application
    Filed: August 16, 2019
    Publication date: March 5, 2020
    Inventors: Alberto Reiner, Giorgio Reiner
  • Publication number: 20200069625
    Abstract: The present invention provides a composition for improving vascular endothelial function, comprising: an ingredient selected from a monounsaturated fatty acid having 20 carbon atoms or more, a salt thereof, and an ester thereof as an active ingredient, in which the ratio of the monounsaturated fatty acid having 20 carbon atoms or more to the total fatty acids in the composition is 10 wt % or greater. The present invention also provides a composition for improving sleep, comprising an ingredient selected from a monounsaturated fatty acid having 20 carbon atoms or more, a salt thereof, and an ester thereof as an active ingredient.
    Type: Application
    Filed: May 23, 2018
    Publication date: March 5, 2020
    Applicant: NIPPON SUISAN KAISHA, LTD.
    Inventors: Rie TSUTSUMI, Jiro TAKEO, Hiroko MIYAHARA, Hiroshi SAKAUE
  • Publication number: 20200069626
    Abstract: The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.
    Type: Application
    Filed: July 31, 2019
    Publication date: March 5, 2020
    Inventors: Jonathan Rowe, Kevin Duffy, John Climax
  • Publication number: 20200069627
    Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Inventors: Mehar Manku, John Climax, David Coughlan, James Dunne
  • Publication number: 20200069628
    Abstract: The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.
    Type: Application
    Filed: July 9, 2019
    Publication date: March 5, 2020
    Inventor: O'Neil W. Guthrie
  • Publication number: 20200069629
    Abstract: The present invention relates to a composition of less than or equal to about 1% of pheromones useful to treat or prevent a behavioral stress problem of a non-human mammal. It also relates to a device comprising said composition and to a method for preventing and/or treating stress-related behaviors in a non-human mammal, by using said composition or device.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 5, 2020
    Inventors: SANDRINE LACOSTE, ALEXANDRA BECK
  • Publication number: 20200069630
    Abstract: Disclosed are compositions and methods for treatment microbial infections. The compositions comprise glycerol monolaurate or a derivative thereof, and can be administered topically, for example, to treat gonorrhea and Zika.
    Type: Application
    Filed: July 10, 2017
    Publication date: March 5, 2020
    Inventors: Marnie L. Peterson, Patrick M. Schlievert
  • Publication number: 20200069631
    Abstract: The present invention includes solid compositions of triglycerides with one or more fatty acids, such as triheptanoin and glycerol phenylbutyrate, and therapeutic use thereof. The solid compositions can be prepared by spray-drying or other processes.
    Type: Application
    Filed: June 19, 2019
    Publication date: March 5, 2020
    Inventors: John KLOPP, Gabrielle MORRIS, Emil KAKKIS, Steven JUNGLES
  • Publication number: 20200069632
    Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 5, 2020
    Inventor: Paresh Soni
  • Publication number: 20200069633
    Abstract: This invention belongs to the modern pharmaceutical field of Traditional Chinese Medicine, and relates to an herbal extract of Chinese Motherwort and its application in pharmacy, which specifically relates to the crystal structure of a Chinese Motherwort extract: Leonurine, and its application in the preparation of medicine. The chemical name of the above-mentioned Leonurine is 4-guanidino-1-)butyl 4-hydroxy-3,5-dimethoxybenzoate. The invention by specific methods prepares leonurine as 6 kinds of crystals with different crystal forms. Specifically, there are six different structures of leonurine sulfate crystals, two of them are hydrate, two are anhydrous crystal form, one is methanol solvate, one is ethanol solvate. The leonurine crystal forms of this invention can applicate in preparing medicine such as insulin sensitizer, hypoglycemic and lipid-lowering drugs.
    Type: Application
    Filed: September 18, 2018
    Publication date: March 5, 2020
    Inventors: Yichun ZHU, Yizhun ZHU, Xinhua LIU, Ying CHEN, Rinkiko SUGURO, Yanfei ZHANG
  • Publication number: 20200069634
    Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.
    Type: Application
    Filed: June 26, 2019
    Publication date: March 5, 2020
    Inventor: Michael E. Silver
  • Publication number: 20200069635
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver cancer and a method for producing same, the composition comprising tetraarsenic hexoxide in which the content of tetraarsenic hexoxide crystalline polymorph a (As4O6-a) is 99% or more. The composition of the present invention exhibits an excellent cancer cell proliferation inhibition effect and thus can be useful as an anticancer drug.
    Type: Application
    Filed: December 4, 2017
    Publication date: March 5, 2020
    Applicant: CHEMAS CO., LTD.
    Inventors: Ill Ju BAE, Zenglin LIAN
  • Publication number: 20200069636
    Abstract: The present invention discloses process for preparation of a CO2 extract of Azadirachta indica and herbal compositions thereof for the treatment of Oral and Colon cancers. More particularly, the invention discloses a process for preparation of a standardized SCO2 extract of Azadirachta indica leaves and herbal compositions of the same for oral use.
    Type: Application
    Filed: August 30, 2019
    Publication date: March 5, 2020
    Inventor: Girish Sudhakar SOMAN
  • Publication number: 20200069637
    Abstract: Described herein are salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, in particular that of formula (I): wherein HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid, benzenesulfonic acid, or sulfuric acid, or hydrates thereof, and crystalline forms thereof characterized by the powder X-ray diffraction diagram and the 13C CP/MAS NMR solid state spectrum. Also described are compositions, methods of use and preparation thereof.
    Type: Application
    Filed: November 7, 2019
    Publication date: March 5, 2020
    Inventors: Marina Gaillard, Philippe Letellier
  • Publication number: 20200069638
    Abstract: The present disclosure relates to chewing gum or lozenge with cannabinoids and menthol including a liquid-filled chewing gum or lozenge with a chewing gum base shell or lozenge candy shell enclosing an internal void therein and a liquid filling in the void, the liquid-filled chewing gum or lozenge including cannabinoids and menthol.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Inventor: Babak Ghalili
  • Publication number: 20200069639
    Abstract: The present disclosure relates to a dissolvable thin oral tape, film or strip or segment thereof composition or device, including a film former, at least one cannabinoid, menthol, caffeine and vitamins.
    Type: Application
    Filed: September 3, 2019
    Publication date: March 5, 2020
    Inventors: Babak Ghalili, Emma Ghalili
  • Publication number: 20200069640
    Abstract: The present invention relates to novel compounds capable of activating BKCa channels. The use of a composition of the present invention can effectively activate the BKCa channels, and can be used for prevention or treatment of various diseases caused by the deactivation of BKCa channels or the degradation of BKCa channel activity.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 5, 2020
    Inventors: Chul Seung PARK, So Jung LEE, Jae Sue CHOI
  • Publication number: 20200069641
    Abstract: Methods and compositions of reducing or eliminating the symptoms of withdrawal from drug or alcohol in drug or alcohol-dependent persons, while restoring the patient to nutritional health. The methods including parenteral administration of solutions containing high doses of ascorbic acid. Compositions of the invention comprise at least about 20%(w), or at least about 25%(w), or at least about 30%(w), or at least about 35%(w), or at least about 38%(w) of ascorbic acid and a local anesthetic.
    Type: Application
    Filed: August 2, 2019
    Publication date: March 5, 2020
    Inventor: Peter J. Muran
  • Publication number: 20200069642
    Abstract: Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (I): The present methods include administering to a subject an effective amount of one or more compounds of Formula (I). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 5, 2020
    Inventors: Yi Tsun Richard KAO, Peng GAO, Xuechen LI, Ming LIU
  • Publication number: 20200069643
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Application
    Filed: March 20, 2018
    Publication date: March 5, 2020
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. LANCIA, Jr., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
  • Publication number: 20200069644
    Abstract: The disclosure generally relates to methods of treating heart failure with Compound 1, 1-((3S,4R)-4-(2,6-difluoro-4-meth oxyphenyl)-2-oxopyrrolidin-3-yl)-3-phenylurea.
    Type: Application
    Filed: May 22, 2018
    Publication date: March 5, 2020
    Inventors: Jacek Ostrowski, Ricardo Garcia, Nicholas R. Wurtz, Nancy Lersey CARSON
  • Publication number: 20200069645
    Abstract: The present invention relates to a use for preventing, alleviating or treating pruritus by administering a pharmaceutical composition comprising a carbamate compound of following Formula 1.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 5, 2020
    Applicant: SK BIOPHARMACEUTICALS CO., LTD.
    Inventor: Min Hee PANG
  • Publication number: 20200069646
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Inventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Ramesh Kumar Sistla
  • Publication number: 20200069647
    Abstract: Pharmaceutical compositions comprising a RelA enzyme inhibitor and a bactericidal antibiotic, wherein said RelA enzyme inhibitor binds to the RelA enzyme in bacteria to reduce biofilm formation and to degrade biofilms that have been formed. The pharmaceutical compositions can be used to treat bacterial biofilm diseases.
    Type: Application
    Filed: May 14, 2018
    Publication date: March 5, 2020
    Applicant: Drexel University
    Inventors: Hai-Feng Ji, Garth David Ehrlich, Donald Carl Hall, Jr., Jaroslaw E. Krol, John P. Cahill
  • Publication number: 20200069648
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: March 2, 2018
    Publication date: March 5, 2020
    Inventors: Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Jonathan Stuart FOOT, Wenbin ZHOU, Wolfgang JAROLIMEK, Alan Duncan ROBERTSON
  • Publication number: 20200069649
    Abstract: This disclosure relates to a pharmaceutical composition for topical use wherein the active pharmaceutical ingredient consists of the co-analgesic phenytoin and at least one further co-analgesic, and a method for producing the pharmaceutical composition. In addition, the disclosure relates to the pharmaceutical composition for use in the treatment of chronic pain.
    Type: Application
    Filed: December 6, 2017
    Publication date: March 5, 2020
    Inventors: David Jos Kopsky, Jan Marius Keppel Hesselink
  • Publication number: 20200069650
    Abstract: The invention relates to a method of treating separation anxiety in companion animals, particularly dogs, comprising administering to a subject in need thereof an effective amount of dexmedetomidine, medetomidine or a pharmaceutically acceptable salt thereof as the active ingredient. The active ingredient is preferably administered oromucosally, e.g. in the form of an oromucosal gel.
    Type: Application
    Filed: December 12, 2017
    Publication date: March 5, 2020
    Inventors: Mira KORPIVAARA, Sauli NIINISTÖ, Sanna ORMIO, Nina SARÉN
  • Publication number: 20200069651
    Abstract: The present invention is directed to compositions and methods for treating ocular conditions, including presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, and glaucoma. The compositions can also be used to potentiate or enhance interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M3 agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound.
    Type: Application
    Filed: April 4, 2019
    Publication date: March 5, 2020
    Inventor: Juan Carlos Abad
  • Publication number: 20200069652
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can more effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Application
    Filed: November 7, 2019
    Publication date: March 5, 2020
    Applicants: CJ HEALTHCARE CORPORATION, RaQualia Pharma Inc.
    Inventors: Ha Jin LEE, Bong Tae KIM, Hyun KIM, Ji Yeon NAM, Jie Eun PARK, Geun Seog SONG, Shin Young RYU, Shinichi KOIZUMI, Nobuyuki TAKAHASHI, Masaomi TAJIMI
  • Publication number: 20200069653
    Abstract: The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and ?-opioid agonistic activity.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventor: Christopher D. Breder
  • Publication number: 20200069654
    Abstract: Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
    Type: Application
    Filed: June 14, 2019
    Publication date: March 5, 2020
    Applicants: NANTBIO, INC., NANTOMICS, LLC, NANT HOLDINGS IP, LLC
    Inventors: Shahrooz RABIZADEH, Oleksandr BUZKO, Paul WEINGARTEN, Heather MCFARLANE, Connie TSAI, Stephen Charles BENZ, Kayvan NIAZI, Patrick SOON-SHIONG
  • Publication number: 20200069655
    Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.
    Type: Application
    Filed: March 13, 2018
    Publication date: March 5, 2020
    Inventors: Martine CLOZEL, Laetitia POUZOL
  • Publication number: 20200069656
    Abstract: Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by “a”, R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.
    Type: Application
    Filed: November 29, 2017
    Publication date: March 5, 2020
    Inventors: Arshad M. Siddiqui, Stephane Ciblat, Lea Constantineau-Forget, Chantal Grand-Maitre, Xiangyu Guo, Jr., Sanjay Srivastava, Gerald W. Shipps, Alan B. Cooper, Vibha Oza, Matthew W. Kostura, Michael Luther, Jedd Levine
  • Publication number: 20200069657
    Abstract: Provided herein are methods of treating cancer with KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Applicant: AMGEN INC.
    Inventors: Brian Alan LANMAN, Victor J. CEE, Alexander J. PICKRELL, Anthony B. REED, Kevin C. YANG, David John KOPECKY, Hui-Ling WANG, Patricia LOPEZ, Kate ASHTON, Shon BOOKER, Christopher M. TEGLEY
  • Publication number: 20200069658
    Abstract: The present invention provides compositions and methods for the treatment of pulmonary hypertension using combination therapy. The combination therapy comprises a compound that increases BMPR2 signaling (BMPR2 activator) in combination with at least one other agent for the treatment of pulmonary hypertension. In certain aspects, the BMPR2 activator can be tacrolimus or a pharmaceutically acceptable solvate, salt, or prodrug thereof.
    Type: Application
    Filed: April 11, 2019
    Publication date: March 5, 2020
    Inventors: Leo GU, Paul C. NAKAGAKI, Narinder S. BANAIT
  • Publication number: 20200069659
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Application
    Filed: May 13, 2019
    Publication date: March 5, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • Publication number: 20200069660
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Application
    Filed: June 6, 2019
    Publication date: March 5, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Publication number: 20200069661
    Abstract: Compositions and methods for treating skin lesions using topically administered antifungal agents such as cyclic peptides, including cyclosporine, tacrolimus, tresperimus, pimecrolimus, sirolimus (rapamycin), everolimus, laflunimus, laquinimod, imiquimod derivatives, esters, salts, and the like and combinations thereof.
    Type: Application
    Filed: August 30, 2019
    Publication date: March 5, 2020
    Applicant: ChemistryRX
    Inventor: Lars BRICHTA
  • Publication number: 20200069662
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
    Type: Application
    Filed: August 2, 2019
    Publication date: March 5, 2020
    Applicant: ANGION BIOMEDICA CORP.
    Inventors: Bijoy PANICKER, Rama K. MISHRA, Dong Sung LIM, Lambertus J.W.M. OEHLEN, Dawoon JUNG
  • Publication number: 20200069663
    Abstract: The present invention encompasses compounds of the formula I which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: August 26, 2019
    Publication date: March 5, 2020
    Inventors: Cédrickx GODBOUT, Martin Thomas FLECK, Hannes Fiepko KOOLMAN
  • Publication number: 20200069664
    Abstract: The present invention provides new methods and kits for treating and preventing bacterial infection.
    Type: Application
    Filed: September 5, 2019
    Publication date: March 5, 2020
    Inventors: Herbert L. Du Pont, Zhi-Dong Jiang, Eric Brown, Charles Darkoh, Pam Golden
  • Publication number: 20200069665
    Abstract: The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity, particularly involved in hypersensitive cough or itching.
    Type: Application
    Filed: August 28, 2018
    Publication date: March 5, 2020
    Applicant: AFASCI, Inc.
    Inventor: Xinmin Xie
  • Publication number: 20200069666
    Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.
    Type: Application
    Filed: June 14, 2017
    Publication date: March 5, 2020
    Inventors: Jing SONG, Lai WANG, Kang Li, Tong ZHANG, Lusong LUO, Min WEI, Zhiyu TANG, Guoliang ZHANG, Changyou ZHOU
  • Publication number: 20200069667
    Abstract: Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV1); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEV1 less than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEV1 and trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: CHRISTOPHER NOEL BARNES, GLENN D. CRATER, EDMUND J. MORAN, SRIKANTH PENDYALA
  • Publication number: 20200069668
    Abstract: Therapeutic combinations of an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of an IRAK4 inhibitor and a BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
    Type: Application
    Filed: March 15, 2019
    Publication date: March 5, 2020
    Inventors: Brian Lannutti, Wayne Rothbaum, Tjeerd Barf, Allard Kaptein
  • Publication number: 20200069669
    Abstract: The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancer. Some aspects of this disclosure provide treatment modalities, methods, strategies, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers with decreased activity or function, or loss of function, of SMARCA4 with a SMARCA2 antagonist.
    Type: Application
    Filed: February 28, 2018
    Publication date: March 5, 2020
    Inventors: Alexandra Rose GRASSIAN, Allison DREW
  • Publication number: 20200069670
    Abstract: The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Inventors: Emmanuelle di Tomaso, Marie-Caroline Germa, Cristian Massacesi, Christine Fritsch, Christian René Schnell, Ranjana Tavorath
  • Publication number: 20200069671
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co., Ltd.
    Inventors: John J. Acton, III, Jianming Bao, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, JR., Zhaoyang Meng, Michael T. Rudd, Oleg B. Selyutin, David M. Tellers, Ling Tong, Jenny Miu-Chun Wai